Laura Friedman
Tickers in This Filing
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
3 flagsRep. Friedman exchanged $1,001 - $15,000 in $ABT on March 24, 2026 — 6 days after the Dental Care for Veterans Act (HR210) was introduced, which could create new revenue streams for dental services.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
3 signalsThese bills and contracts share tickers or sectors with this filing's trades.
To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
The SUPER BUGS Act (HR7879) is a procedural bill with zero funding, no procurement mechanism, and no regulatory impact. It requires the State Department to develop a strategy for international pandemic product collaboration. Market impact is negligible — recent price moves in $PFE (-1.41% 7d), $MRNA (-7.27% 7d), $JNJ (+1.01% 7d), and $GILD (+0.18% 7d) reflect broader sector trends, not this legislation.
Dental Care for Veterans Act
The Dental Care for Veterans Act (HR210) expands VA dental eligibility to all enrolled veterans, creating an estimated $5-10B annual procurement opportunity for dental suppliers. The bill has 95 cosponsors and passed committee hearings but no appropriations are authorized. HSIC and XRAY are the strongest structural beneficiaries given their pure-play dental exposure.
To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.
HR7867 (Infant Formula Safety Modernization Act) directly burdens Abbott Laboratories ($ABT) with new mandatory testing and notification requirements at a time when $ABT is trading at $90.35, just $0.02 above its 52-week low. The bill is early-stage (referred to committee) but represents an additional regulatory headwind for the dominant US infant formula manufacturer already under FDA scrutiny after the 2022 plant shutdown.
Other Filings by Laura Friedman
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.